hsa-miR-141

ncRNA information

ncRNA name

hsa-miR-141

Specific or universal ncRNAs

Universal ncRNAs

Class

MicroRNA

Biomarker

Yes

Biomarker application

Treatment

Upstream regulatory factors

Not available

Downstream target

PDCD4

Cancer information

Cancer name

Non-Small Cell Lung Cancer

Cancer site

Lung

Treatment information

Treatment type

Chemotherapy

Drug

Cisplatin

Impact of wild-type ncRNA on chemotherapy resistance

Impact of knockdown of ncRNA on chemotherapy resistance

Down

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

MiR-141 might be a therapeutic method to overcome cisplatin resistance in clinical practice.

Tissue resource

human lung adenocarcinoma cell lines A549

human lung adenocarcinoma cisplatin-resistant cell lines A549/DDP

Experiment

qRT-PCR,Western blot,Luciferase reporter assay


Institute

Keygen Biotechnology Co. Ltd

Country

China

Continent

Asia